Highlights of the 2019 EASD Congress

David R. Matthews, President of EASD explains the EASD statement on the new guidelines and summarize the highlights of the congress.

DAPA HF: The Dapagliflozin And Prevention Of Adverse‑ outcomes In Heart Failure Trial

The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes, pre-diabetes and a normal glycated haemoglobin (HbA1c) in DAPA-HF.

Early intervention with oral semaglutide and long term safety

Prof. Melanie Davies speaks about the two torchbearers in cardiovascular protection in diabetes, the SGLT2 inhibitors and GLP-1 analogs.

VERIFY and CONCLUDE study

Prof. Stefano Del Prato summarize the new findings of the VERIFY and CONCLUDE studies.

Cardiorenal risk in type 2 diabetes

Prof. Tina Vilsbøll discusses the current opinion about cardiorenal risk in patients with T2D.

Clinical properties and differences between GLP-1 agonists

Michael A. Nauck speaks about on the combinations of DPP4 inhibitors and SGLT2 inhibitors.

Why We Should Still Care about Glycemic Lowering Strategies for Type 2 Diabetes

Prof. Hertzel Gerstein speaks about the question of the importance of glycemic control in the management of type 2 diabetes.

Diabetic retinopathy: Is the eye a mirror of the brain?

Prof. Coen D. A. Stehouwer speaks about the connection between diabetic retinopathy and other complications of diabetes.